A new trading day began on Tuesday, with Travere Therapeutics Inc (NASDAQ: TVTX) stock price up 4.51% from the previous day of trading, before settling in for the closing price of $15.96. TVTX’s price has ranged from $7.93 to $25.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -3.34% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 72.68%. With a float of $87.44 million, this company’s outstanding shares have now reached $88.79 million.
In an organization with 385 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 92.23%, operating margin of -81.81%, and the pretax margin is -82.6%.
Travere Therapeutics Inc (TVTX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Travere Therapeutics Inc is 1.54%, while institutional ownership is 115.48%. The most recent insider transaction that took place on Jul 01 ’25, was worth 11,940. In this transaction CHIEF MEDICAL OFFICER of this company sold 815 shares at a rate of $14.65, taking the stock ownership to the 88,787 shares. Before that another transaction happened on May 05 ’25, when Company’s CHIEF FINANCIAL OFFICER sold 1,784 for $21.05, making the entire transaction worth $37,553. This insider now owns 93,126 shares in total.
Travere Therapeutics Inc (TVTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 72.68% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Here are Travere Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.80, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach 0.57 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.11 million. That was inferior than the volume of 1.63 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 73.77%.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 41.16%, which indicates a significant decrease from 82.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.66 in the past 14 days, which was lower than the 0.90 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.38, while its 200-day Moving Average is $18.00.
